~~<i id='9D9FA90682'><strike id='9D9FA90682'><tt id='9D9FA90682'><pre id='9D9FA90682'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：focus 2025-09-03 09:19:08 - browse：1

Photo illustration of a single pill on a large white field – opinion coverage from STAT — Adobe

This time last year, members of Congress were working around the clock to draft and pass the Inflation Reduction Act.

One of their goals was to address government spending on health care. But they specifically didn’t want to discourage research into rare disease treatments, so they exempted some of these so-called orphan drugs from the law.

Unfortunately, the exemptions aren’t working as intended. Unless Congress acts, the IRA threatens to unravel one of America’s greatest medical and public policy success stories: the explosion of new treatments for patients living with rare diseases.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： DeSantis wants to import drugs. Biden’s FDA blasted his plan

focus

knowledge

Wikipedia

explore

hotspot

entertainment

DrugmakersalreadybetbigonmRNAforcancer.NowPresidentBidenisgoingin,too?AnnaMoneymaker/GettyImagesWASH

WSS

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Roche acquires Telavant from Roivant, adding experimental IBD treatment

As obesity drug market grows, telehealth companies court payers

Health tech investors get more selective as pandemic boom fades

FDA advisory panel to debate high blood pressure devices

focus

hotspot

focus

Guidelines to prevent youth baseball injuries need more muscle

Study on Amgen’s bispecific immunotherapy produces positive data

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

J&J lung cancer data amount to new salvo against AstraZeneca

Medicare proposal to cover medical devices draws a mixed reaction

Roivant's CEO is a star, but biotech's black hole persists

Drug repurposing or repositioning? The language matters

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Psychedelics group wrestles with new pharma identity

Meadows told special counsel he could not recall Trump ever declassifying Mar

knowledge

People can get long Covid without testing positive for virus: Study

How to make over

Roche drug slashes death risk in early

Republicans love RFK Jr. What's that tell us about health in 2024?

Trans patients at the end of life deserve respect and dignity

STAT Summit: How researchers deal with rejection

Wikipedia

explore

hotspot

entertainment